TimesNowNews reports that the University of California, Los Angeles (UCLA) recently concluded from a study that men with low or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment. The study showed that this type of radiation—stereotactic body radiotherapy—is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run. For the study, the team included 2,142 men with low or intermediate-risk prostate cancer who were treated with stereotactic body radiotherapy. They were followed for a median of 6.9 years. Nearly, 53% of men had low-risk disease, 32% had a less aggressive intermediate-risk disease and 12% had a more aggressive form of the intermediate-risk disease.
In addition, the recurrence rate for men with the low-risk disease was 4.5%, 8.6% for the less aggressive intermediate-risk, and 14.9% for the more aggressive intermediate-risk group, findings published in the journal JAMA Network Open showed. Overall, the recurrence rate for the intermediate-risk disease was 10.2%.
Amar Kishan, Assistant Professor, UCLA